Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion
German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...
Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane
Alcon reported May 6 that its Q1-2026 net sales were $2.69 billion, a 10 percent increase (+6 percent cc) over $2.45 billion in Q1-2025. Surgical net sales totaled $1.46 billion, consisting of $438...
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...
Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar
Sweden’s Xbrane Biopharma announced April 30 that it had resubmitted the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA. A complete response letter from...
Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate
South Korea’s Novelty Nobility announced May 4 that it had expanded its manufacturing agreement with AGC Biologics to advance retinal disease candidate NN4101 through process development and GMP ma...
Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate
Kubota Vision and Laboratoires Kôl announced May 4 that they had signed a supply and licensing agreement to bring emixustat hydrochloride, an oral treatment candidate for Stargardt disease, to pati...
US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program
Opus Genetics announced May 4 that the US FDA had accepted OPGx-LCA5, a gene therapy candidate targeting Leber congenital amaurosis type 5, into the new Rare Disease Evidence Principles (RDEP) prog...
BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced April 21 that it had initiated a rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califor...
Past News Stories
US FDA Gives Green Light to Trial of LayerBio’s OcuRing-K for Post-op Inflammation and Pain
Israel’s PRF Technologies and its majority-owned subsidiary LayerBio reported on April 28 that the US FDA had signed off on their investigational new drug (IND) application, allowing LayerBio to pr...
Formosa, Singapore Eye to Explore New Treatments for Corneal, Ocular Surface Disease
Taiwan’s Formosa Pharmaceuticals and the Singapore Eye Research Institute (SERI) have teamed up to address unmet needs in corneal and ocular surface disease, Formosa announced April 30. The partner...
EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate
Ray Therapeutics announced April 29 that the European Medicines Agency had granted Priority Medicines (PRIME) designation to RTx-015, its optogenetic therapy candidate for retinitis pigmentosa (RP)...
New Law in Tennessee Expands ODs’ Scope to Include SLT, LPI, YAG Capsulotomy
Tennessee has become the 16th US state to pass a law expanding optometrists’ scope of practice to include in-office laser procedures. Senate Bill 2076, signed into law by Gov. Bill Lee on April 14,...
Inventors of Luxturna Win $3 Million Breakthrough Prize
Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...
Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion
Swiss company Roche reported April 23 that Vabysmo sales in Q1-2026 were CHF 1.024 billion ($1.3 billion, calculated for March 31, 2026), up 13 percent in constant currency from CHF 1.018 billion i...
New OD Survey Looks at Factors Shaping Premium IOL Education Before Referral
Optometrists play an increasingly important role in educating patients about cataract surgery prior to referral, as those patients’ expectations continue to rise. Key findings from Market Scope’s i...
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026
The US Centers for Medicare and Medicaid Services (CMS) issued J-codes in Q1-2026 for Harrow’s Iopidine and Glaukos’ Epioxa and Epioxa HD. In addition, the CMS issued Q-codes for Zydec’s interchang...
Revenio Group to Acquire Visionix in $341 Million Deal
Finland’s Revenio Group, parent of ophthalmic diagnostic company iCare, announced April 13 that it would acquire France-based Visionix in a deal worth €290 million ($341 million). Revenio said that...
US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO
Genentech announced April 9 that the US FDA had approved the extension of dosing intervals for Vabysmo (faricimab-svoa) beyond six months for patients with macular edema due to retinal vein occlusi...
Lenz Submits Marketing Application for Vizz Presbyopia Drop in the UK
Lenz Therapeutics announced April 20 that it had submitted a marketing authorization application to the UK’s Medicines and Healthcare Products Regulatory Agency for Vizz, an eye drop targeting pres...
Santen to Market Five of AbbVie’s Glaucoma Drops in China
Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.